Receive The Newest Study Notifications

-Biogen (Nasdaq: BIIB) today announced that it has entered into an agreement to acquire Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for...

-Medicortex Finland Oy (http://www.medicortex.fi), a biotechnology company developing a diagnostic kit for brain injury detection based on a medical breakthrough biomarker, completed collection of samples in its second large clinical study. The trial recruited...

Vascular Graft Solutions Ltd. (VGS) announces the completion of patient enrollment in the company's US Investigational Device Exemption (IDE) randomized, controlled pivotal study, evaluating the efficacy of the VEST external support for saphenous vein grafts in...

- A Potential Global First-in-Class Long-Acting Recombinant IL-7 Immunotherapy I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases,...

The symptoms of cognitive impairment in people with Parkinson’s Disease (PD) are significant. In this webinar, the featured speakers will address important trends in the identification of patient populations suitable for trials of cognition-enhancing or...

– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in genes such as NPM1 – – Phase 1 clinical trial in relapsed or...

Company anticipates announcing topline efficacy and safety results in July 2019 SAN JOSE, Calif., March 4, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology...

Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with platinum-sensitive relapsed ovarian cancer, regardless of BRCA status Rucaparib provided statistically significant improvement in progression-free survival (PFS) versus...

- 80 to 100% of BE ABLE 1 responders maintained a response of at least 90% disease improvement (PASI90) over 60 weeks with bimekizumab - These positive results mark the longest-term data to date demonstrating durable PASI90/PASI100 outcomes to 60 weeks with...

Biogen to acquire Nightstar Therapeutics for $25.50 per share Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited retinal diseases that would otherwise lead to blindness Nightstar has two...

Phase 2 Clinical Data Presented at ASCO-SITC Clinical Immuno-Oncology Symposium Xenogenization through chemotherapy-induced genetic mutations (alkylating agents such as temozolomide) or drug-induced immunologic cell death can be effectively leveraged to for successful...

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced final results from the efficacy...

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V: TBP) (OTCQB: TBPMF), a global leader in cannabinoid-derived drug development and discovery, is pleased to announce completion of the first double-blind, randomized and placebo-controlled Phase 2 clinical trial...

CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed and accepted CytoDyn’s request and plan to submit on a...

No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...

First patient enrolled in the MOMENTUM study Trial being conducted under FDA Special Protocol Assessment (SPA) Topline results anticipated in 1Q 2020 Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for...

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced that is has completed enrollment in the Phase 2a clinical trial...

– CAMP-1 and CAMP-2 trials of VP-102 for the treatment of molluscum contagiosum successfully met their primary endpoints – – Molluscum contagiosum is a highly contagious, significantly undertreated viral skin disease that affects approximately six million people in...

Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, announced today the completion of patient enrollment for a Phase III monotherapy trial of HMS5552...

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of LYNPARZA...